Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study.
- Elens, Laure
- Becker, Matthijs L
- Haufroid, Vincent
- Hofman, Albert
- Visser, Loes E
- Uitterlinden, André G
- Stricker, Bruno Ch
- van Schaik, Ron H N
Publication date
January 2011
DOI Publisher
Ovid Technologies (Wolters Kluwer Health) ISSN
1744-6872Abstract
CYP3A4 is involved in the oxidative metabolism of many drugs and xenobiotics including the HMG-CoA reductase inhibitor simvastatin. The objective of this study was to investigate whether a new CYP3A4 functional single nucleotide polymorphism (SNP) in intron 6 (CYP3A4*22) modifies the effect of simvastatin on total cholesterol (TOTc) or LDL cholesterol (LDLc) reduction in a population-based cohort study
Add to ORKG